News
ESLA
1.205
+0.42%
0.005
Weekly Report: what happened at ESLA last week (0504-0508)?
Weekly Report · 3d ago
Estrella Immunopharma to join D. Boral Capital Global Conference investor meetings
PUBT · 05/05 12:02
Weekly Report: what happened at ESLA last week (0427-0501)?
Weekly Report · 05/04 10:09
Estrella Immunopharma CFO Jiandong Xu buys common shares worth $1,437.8
PUBT · 04/30 01:37
Weekly Report: what happened at ESLA last week (0420-0424)?
Weekly Report · 04/27 10:11
Weekly Report: what happened at ESLA last week (0413-0417)?
Weekly Report · 04/20 10:07
Weekly Report: what happened at ESLA last week (0406-0410)?
Weekly Report · 04/13 10:11
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/10 21:13
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 04/07 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 04/06 17:05
Weekly Report: what happened at ESLA last week (0330-0403)?
Weekly Report · 04/06 10:11
Weekly Report: what happened at ESLA last week (0323-0327)?
Weekly Report · 03/30 10:11
Zacks Small-Cap Research initiates coverage of Estrella Immunopharma with $12/share valuation
Reuters · 03/23 12:03
Weekly Report: what happened at ESLA last week (0316-0320)?
Weekly Report · 03/23 10:08
Estrella Immunopharma FY 2025 net loss widened 48.86% to USD 13.1 million
Reuters · 03/18 10:03
Weekly Report: what happened at ESLA last week (0309-0313)?
Weekly Report · 03/16 10:08
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/10 21:06
Weekly Report: what happened at ESLA last week (0302-0306)?
Weekly Report · 03/09 10:08
Weekly Report: what happened at ESLA last week (0223-0227)?
Weekly Report · 03/02 10:07
Weekly Report: what happened at ESLA last week (0216-0220)?
Weekly Report · 02/23 10:07
More
Webull provides a variety of real-time ESLA stock news. You can receive the latest news about Estrella Immunopharma through multiple platforms. This information may help you make smarter investment decisions.
About ESLA
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).